TGen (City of Hope) launched JAYseq™, a clinical whole-genome sequencing test tailored for multiple myeloma with results delivered in about three days. The offering is positioned as a fast, comprehensive alternative to slower or less integrated sequencing workflows for complex MM analysis. TGen says JAYseq is designed to provide end-to-end genomic readouts for clinical decision-making, focusing on the disease’s characteristic biology and the need for broad coverage. The test’s operational aim is to compress turnaround time to help clinicians act within treatment timelines. The launch also reflects growing demand for clinically actionable sequencing that can support both routine care and trials, particularly in settings where minimal residual disease and disease monitoring have become core endpoints. For the genomics market, it adds pressure for competing labs to shorten time-to-result while preserving broad analytical scope.